ImmunoGen Inc
Performance History
| Key Stats | |
|---|---|
| Open | $29.20 |
| Prev. Close | $16.06 |
| EPS | -0.28 |
| Dividend | $0.00 |
| Next Earnings Date | Jul 31, 2023 |
| Dividend Yield % | - |
| Market Cap | $7.81B |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 28.76 | 29.44 |
| 52 Week Range | 3.61 | 29.44 |
| Ratios | |
|---|---|
| P/B Ratio | 7.61 |
| Revenue | $287.61M |
| Operating M. % | 22.88% |
| Earnings | -$73.52M |
| Earnings Growth % | 637.72% |
| EBITDA Margin % | -27.28% |
| ROE % | -19.88% |
| EPS | -0.28 |
Score Breakdown
All Score (81 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| IMGN | Market | |
|---|---|---|
| Value | 42 | 42 |
| Quality | 79 | 46 |
| Ownership | 56 | 39 |
| Growth | 84 | 44 |
| Dividends | - | 32 |
All Score (81 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About ImmunoGen Inc (IMGN)
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Mark Joseph Enyedy
- Headquarters
- Waltham
- Employees
- 277
Keep an eye on ImmunoGen Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.